U.S. Markets closed

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9341-0.0332 (-3.43%)
At close: 04:00PM EDT
1.0200 +0.09 (+9.20%)
After hours: 05:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9673
Bid0.9000 x 1300
Ask1.0200 x 800
Day's Range0.8800 - 0.9808
52 Week Range0.7280 - 19.1400
Avg. Volume280,366
Market Cap24.488M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-4.2780
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.38
  • Zacks

    Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now

    After losing some value lately, a hammer chart pattern has been formed for Applied Therapeutics Inc. (APLT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

  • GlobeNewswire

    Applied Therapeutics Reports Second Quarter 2022 Financial Results

    Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2H 2022, including Galactosemia 12 month data analysis, SORD Deficiency biomarker data, and DbCM full enrollment NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: A

  • GlobeNewswire

    Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference

    Gold sponsor of the 2022 Galactosemia Foundation Conference; new website and educational resources as part of ongoing commitment to the Galactosemia communityApplied Therapeutics to present research and clinical update NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced its spons